LATEST
Janel agreed to acquire EnCor BiotechnologynewNightfood Holdings acquired Jun Long Machine IndustrialnewClimb Global Solutions acquired NeoVADnewValor Energy agreed to acquire Glorious StarOakley Capital / Global Loan Agency ServicesTA Associates / MedEnvision: majority stakeLSEG agreed to acquire OctusStord / AMS Fulfillment: investmentCencora agreed to acquire American Oncology NetworkAPEX / KoraiSmith & Wesson Brands agreed to acquire Long Range IntermediateBose acquired Skullcandy
Open App
ClosedPublished 15 Sep 2022

Lisata Therapeutics, Inc. /
Cend Therapeutics, Inc.

Lisata Therapeutics and Cend Therapeutics complete business combination

Terms
Not stated
Stage
Closed
Source · 15 Sep 2022
See the source
01 / BuyerLisata Therapeutics, Inc.
02 / TargetCend Therapeutics, Inc.
01

What happened

Lisata Therapeutics, Inc. completed its business combination with Cend Therapeutics, Inc. on Sept. 15, 2022, with Cend surviving as a wholly owned subsidiary.

Lisata issued common stock to Cend’s stockholders at an exchange ratio of 0.5338 shares for each share of Cend common and preferred stock.

02

The source

Everything on this page comes from the source below.

01
Source · Source

Lisata Therapeutics and Cend Therapeutics complete business combination

This document is the source for the companies, stage and people on this page.

Original filingUnlock with Pro
03

Timeline

Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.

  1. Closed

    The source this page is built from.

  2. Published by the source

    The source this page is built from.

The same firms, in other deals

The firms' deal history and connections across other deals.

These firms' full profiles are part of Pro.

Request accessAlready invited? Sign in

Carrywatch Pro is by invitation. An invite lets you buy Pro.